scispace - formally typeset
Open AccessJournal ArticleDOI

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

- 14 Apr 2022 - 
- Vol. 386, Iss: 15, pp 1397-1408
TLDR
Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan-human-coronavirus activity in vitro as discussed by the authors .
Abstract: 
Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro.

read more

Citations
More filters
Journal ArticleDOI

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

R. Najjar-Debbiny, +7 more
- 02 Jun 2022 - 
TL;DR: Paxlovid appears to be more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease and in real-life settings, Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality.
Journal ArticleDOI

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

Ryuta Uraki, +67 more
- 16 May 2022 - 
TL;DR: In this article , the authors evaluated the replicative ability and pathogenicity of authentic infectious BA.2 isolates in immunocompetent and human ACE2-expressing mice and hamsters.
Journal ArticleDOI

Nirmatrelvir Plus Ritonavir: First Approval

Yvette N. Lamb
- 19 Mar 2022 - 
TL;DR: Nirmatrelvir plus ritonavir (Paxlovid™; Pfizer) as mentioned in this paper is a co-packaged combination of nirm atrelvir and riton avir tablets, intended for co-administration and developed for the treatment and post-exposure prophylaxis of coronavirus disease 2019 (COVID-19).
Journal ArticleDOI

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Adarsh Bhimraj, +16 more
- 05 Sep 2022 - 
TL;DR: Develop evidence-based, rapid, living guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19.
Journal ArticleDOI

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge

TL;DR: The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-risk, unvaccinated patients infected with the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as discussed by the authors .
References
More filters
Journal ArticleDOI

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu, +1 more
- 07 Apr 2020 - 
TL;DR: Hospitalised COVID-19 patients are frequently elderly subjects with co-morbidities receiving polypharmacy, all of which are known risk factors for d
Journal ArticleDOI

Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19.2 million participants

Mariachiara Di Cesare, +741 more
- 02 Apr 2016 - 
TL;DR: The posterior probability of meeting the target of halting by 2025 the rise in obesity at its 2010 levels, if post-2000 trends continue, is calculated.
Journal ArticleDOI

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study

Gregory A. Roth, +68 more
- 22 Dec 2020 - 
TL;DR: CVD burden continues its decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized rate of CVD has begun to rise in some locations where it was previously declining in high- income countries.
Journal ArticleDOI

A multiple testing procedure for clinical trials.

Peter C. O'Brien, +1 more
- 01 Sep 1979 - 
TL;DR: The overall size of the procedure is shown to be controlled with virtually the same accuracy as the single sample chi-square test based on N(m1 + m2) observations and the power is found to bevirtually the same.
Journal ArticleDOI

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.

Annemarie B Docherty, +25 more
- 22 May 2020 - 
TL;DR: In study participants, mortality was high, independent risk factors were increasing age, male sex, and chronic comorbidity, including obesity, and the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks is shown.
Related Papers (5)

COVID-19, coronavirus, SARS-CoV-2 and the small bowel.

Klaus Mönkemüller, +2 more
- 28 Apr 2020 - 

Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV).

Y.M. Dennis Lo, +1 more
- 01 Apr 2020 - 

Seroconversion against SARS‐CoV‐2 occurred after the recovery in patients with COVID‐19

Shinya Yamamoto, +8 more
- 01 Feb 2021 - 

The COVID-19 conundrum: SARS-CoV-2 is not present in bile.

Tousif Kabir, +5 more
- 01 Sep 2020 - 

2019 Novel Coronavirus (2019-nCoV) Pneumonia

Peng Liu, +1 more
- 04 Feb 2020 -